MCID: ADL019
MIFTS: 33

Adult Fibrosarcoma malady

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Adult Fibrosarcoma

Aliases & Descriptions for Adult Fibrosarcoma:

Name: Adult Fibrosarcoma 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3516
NCIt 47 C7809
UMLS 69 C0278595

Summaries for Adult Fibrosarcoma

MalaCards based summary : Adult Fibrosarcoma is related to patent ductus arteriosus and bicuspid aortic valve with hand anomalies and intracystic papillary adenoma. An important gene associated with Adult Fibrosarcoma is NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are G-protein signaling_H-RAS regulation pathway and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Related phenotypes are growth/size/body region and cardiovascular system

Related Diseases for Adult Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Adult Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 10.3 ETV6 NTRK3
2 intracystic papillary adenoma 10.3 ETV6 NTRK3
3 anterior cerebral artery infarction 10.3 ETV6 NTRK3
4 intestinal obstruction 10.3 ETV6 NTRK3
5 rohhad 10.2 COL1A1 PDGFB
6 verruciform xanthoma of skin 10.2 MB MYOD1
7 cellular phase chronic idiopathic myelofibrosis 10.2 ETV6 NTRK3
8 intrahepatic bile duct cystadenoma 10.2 MB MYOD1
9 benign schwannoma 10.2 COL1A1 PDGFB
10 transitional cell carcinoma 10.2 MB MYOD1
11 ovarian cystadenoma 10.2 MB MYOD1
12 bile duct rhabdomyosarcoma 10.2 MB MYOD1
13 conjunctival disease 10.2 MYOD1 WT1
14 acromegaly 10.2 COL1A1 PDGFB
15 dyslexia 10.2 COL1A1 PDGFB
16 intracranial liposarcoma 10.2 MB PDGFB
17 plexopathy 10.1 MB WT1
18 endodermal sinus tumor 10.1 MB MYOD1
19 long qt syndrome 1 10.1 COL1A1 FDPS
20 glomerulonephritis 10.1 MB MYOD1
21 peripheral osteosarcoma 10.1 PDGFB WT1
22 diffuse glomerulonephritis 10.1 ETV6 NTRK3 WT1
23 extraosseous osteosarcoma 10.1 HRAS MYOD1
24 t-cell childhood lymphoblastic lymphoma 10.1 MB NTRK3
25 testis sarcoma 10.1 MYOD1 MYOG
26 amelogenesis imperfecta-gingival hyperplasia syndrome 10.1 MYOD1 MYOG
27 lung benign neoplasm 10.1 MYOD1 WT1
28 gestational choriocarcinoma 10.1 COL1A1 PDGFB WT1
29 subacute leukemia 10.0 MB MYOG
30 non-distal monosomy 10q 10.0 ETV6 HRAS NTRK3
31 gallbladder pleomorphic giant cell adenocarcinoma 10.0 HRAS WT1
32 uterine corpus endometrial stromal sarcoma 10.0 HRAS WT1
33 nasal cavity adenocarcinoma 10.0 ETV6 NTRK3
34 intermixed schwannian stroma-rich ganglioneuroblastoma 10.0 HRAS WT1
35 peroxisome biogenesis disorder 7a 9.9 ETV6 HRAS WT1
36 mixed type rhabdomyosarcoma 9.9 MB MYOD1 MYOG
37 hemophagocytic lymphohistiocytosis 9.9 ETV6 HRAS WT1
38 childhood medulloblastoma 9.9 MB MYOD1 MYOG
39 mediastinum rhabdomyosarcoma 9.9 MB MYOD1 MYOG
40 arthus reaction 9.9 HRAS MB
41 hormone producing pituitary cancer 9.9 MYOD1 MYOG WT1
42 nodular tenosynovitis 9.9 MYOD1 MYOG WT1
43 diabetes persistent mullerian ducts 9.9 MYOD1 MYOG WT1
44 embryonal extrahepatic bile duct rhabdomyosarcoma 9.9 MB MYOD1 MYOG
45 adenosarcoma 9.9 MB MYOG WT1
46 fibrosarcoma 9.9
47 cerebral cavernous malformations-2 9.8 MYOD1 MYOG WT1
48 mediastinum sarcoma 9.8 MB MYOD1 MYOG WT1
49 rhabdomyosarcoma 2, alveolar 9.8 MB MYOD1 MYOG WT1
50 prostate rhabdomyosarcoma 9.7 HRAS MB MYOD1 MYOG

Graphical network of the top 20 diseases related to Adult Fibrosarcoma:



Diseases related to Adult Fibrosarcoma

Symptoms & Phenotypes for Adult Fibrosarcoma

MGI Mouse Phenotypes related to Adult Fibrosarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.09 COL1A1 ETV6 HRAS MB MYOD1 MYOG
2 cardiovascular system MP:0005385 10.08 COL1A1 ETV6 HRAS MB MYOD1 NTRK3
3 mortality/aging MP:0010768 10.02 COL1A1 ETV6 HRAS MB MYOD1 MYOG
4 homeostasis/metabolism MP:0005376 10.01 COL1A1 ETV6 HRAS MB MYOD1 MYOG
5 embryo MP:0005380 9.93 WT1 COL1A1 ETV6 MB MYOG PDGFB
6 muscle MP:0005369 9.8 COL1A1 MB MYOD1 MYOG PDGFB WT1
7 no phenotypic analysis MP:0003012 9.76 COL1A1 ETV6 HRAS MYOD1 MYOG NTRK3
8 neoplasm MP:0002006 9.65 COL1A1 ETV6 HRAS MYOD1 WT1
9 normal MP:0002873 9.5 MYOG NTRK3 WT1 COL1A1 ETV6 HRAS
10 respiratory system MP:0005388 9.23 COL1A1 HRAS MB MYOD1 MYOG NTRK3

Drugs & Therapeutics for Adult Fibrosarcoma

Drugs for Adult Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Lenograstim Approved Phase 3,Phase 2 135968-09-1
6
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
7
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
15 Isophosphamide mustard Phase 3,Phase 2,Phase 1
16 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Etoposide phosphate Phase 3,Phase 2
19 Imatinib Mesylate Phase 2, Phase 3,Phase 1 123596
20 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
21 Anti-Allergic Agents Phase 3
22 Antipruritics Phase 3
23 Dermatologic Agents Phase 3
24 Gastrointestinal Agents Phase 3
25 Histamine Antagonists Phase 3
26 Histamine H1 Antagonists Phase 3
27
Histamine Phosphate Phase 3 51-74-1 65513
28 Neurotransmitter Agents Phase 3
29
Serotonin Phase 3 50-67-9 5202
30 Serotonin Agents Phase 3
31 Serotonin Antagonists Phase 3
32
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Estramustine Approved Phase 1, Phase 2 2998-57-4 18140 259331
39
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
40
Vinblastine Approved Phase 1, Phase 2 865-21-4 13342 241903
41
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 60780 44424639
42
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
43
Thiotepa Approved Phase 2 52-24-4 5453
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
46
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
47
nivolumab Approved Phase 2 946414-94-4
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
50
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 85)
id Name Status NCT ID Phase
1 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
3 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
8 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
9 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
10 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
13 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
14 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3
15 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
16 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
17 Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2
18 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
19 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
20 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
21 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
22 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
23 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
24 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
25 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
26 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
27 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
30 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
31 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer Completed NCT00326495 Phase 2
32 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00004105 Phase 1, Phase 2
33 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
34 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
35 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
36 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2
37 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
38 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2
39 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2
40 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
41 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
42 Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans Completed NCT00243191 Phase 2
43 Imatinib in Dermatofibrosarcoma Protuberans (DFSP) Completed NCT00122473 Phase 1, Phase 2
44 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2
45 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2
46 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
47 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
48 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
49 Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors Recruiting NCT02637687 Phase 1, Phase 2
50 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2

Search NIH Clinical Center for Adult Fibrosarcoma

Genetic Tests for Adult Fibrosarcoma

Anatomical Context for Adult Fibrosarcoma

Publications for Adult Fibrosarcoma

Articles related to Adult Fibrosarcoma:

id Title Authors Year
1
Adult fibrosarcoma: surgical management in developing countries. ( 25528208 )
2015
2
Adult fibrosarcoma of the wrist: a case report. ( 22689150 )
2012
3
Gains of 12q are the most frequent genomic imbalances in adult fibrosarcoma and are correlated with a poor outcome. ( 11921284 )
2002
4
Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarcoma suggests a close relationship to dermatofibrosarcoma protuberans. ( 11329146 )
2001

Variations for Adult Fibrosarcoma

Expression for Adult Fibrosarcoma

Search GEO for disease gene expression data for Adult Fibrosarcoma.

Pathways for Adult Fibrosarcoma

Pathways related to Adult Fibrosarcoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.82 HRAS PDGFB
2 10.78 MYOD1 MYOG PDGFB
3
Show member pathways
10.62 FDPS HRAS
4 10.1 COL1A1 PDGFB

GO Terms for Adult Fibrosarcoma

Biological processes related to Adult Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 ETV6 HRAS MYOD1 MYOG WT1
2 positive regulation of transcription, DNA-templated GO:0045893 9.65 COL1A1 MYOD1 MYOG PDGFB WT1
3 positive regulation of DNA replication GO:0045740 9.57 HRAS PDGFB
4 cellular response to estradiol stimulus GO:0071392 9.56 MYOD1 MYOG
5 skeletal muscle fiber development GO:0048741 9.55 MYOD1 MYOG
6 positive regulation of muscle cell differentiation GO:0051149 9.54 MYOD1 MYOG
7 activation of protein kinase B activity GO:0032148 9.52 NTRK3 PDGFB
8 cellular response to retinoic acid GO:0071300 9.5 COL1A1 MYOG NTRK3
9 positive regulation of myoblast differentiation GO:0045663 9.49 MYOD1 MYOG
10 positive regulation of myoblast fusion GO:1901741 9.48 MYOD1 MYOG
11 myoblast differentiation GO:0045445 9.46 MYOD1 MYOG
12 positive regulation of actin cytoskeleton reorganization GO:2000251 9.43 HRAS NTRK3
13 myotube differentiation GO:0014902 9.4 MYOD1 MYOG
14 positive regulation of skeletal muscle fiber development GO:0048743 9.37 MYOD1 MYOG
15 heart development GO:0007507 9.26 MB NTRK3 PDGFB WT1
16 muscle cell fate commitment GO:0042693 9.16 MYOD1 MYOG
17 positive regulation of cell migration GO:0030335 8.92 COL1A1 HRAS NTRK3 PDGFB

Molecular functions related to Adult Fibrosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.46 ETV6 MYOD1 MYOG WT1
2 E-box binding GO:0070888 9.26 MYOD1 MYOG
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.13 ETV6 MYOD1 MYOG
4 platelet-derived growth factor binding GO:0048407 8.62 COL1A1 PDGFB

Sources for Adult Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....